TOP 10 Cancer drugs in the world easy to use .

The first cancer drug to reach “blockbuster” status with sales of more than $1 billion was paclitaxel in 1997. Twenty years later, the median annual cost of a new cancer drug launched in 2017 exceeded $150,000, compared to $79,000 for the new cancer drugs launched in 2013, according to a report issued last year by IQVIA™ Institute for Human Data Science.

IQVIA’s report, “Global Oncology Drug Trends 2018,” showed that in the U.S., spending on cancer treatments had doubled since 2012, reaching almost $50 billion in 2017—compared with $60 billion in oncology drug costs in the rest of the world. Two thirds of the jump in U.S. cancer drug sales came from treatments launched within the previous five years, with 14 new cancer therapeutics launched in 2017 alone.

Even more sobering, IQVIA projected that U.S. cancer drug prices are expected to double again by 2022, to $100 billion, based on annual growth of 12–15%. An equivalent amount of sales is also forecast outside the U.S., where sales are expected to grow at a slightly smaller pace of between 10% and 13% annually. As a result, the global cancer drug market is projected to reach $200 billion in three years.

The challenge of containing the cost of cancer drugs was cited by panelists at “Advancing Quality Oncology Care In the Evolving Value-Based Care Landscape,” a panel discussion held April 16 in White Plains, NY, by The American Journal of Managed Care® (AJMC®) with its Institute for Value-Based Medicine®.

Manuel C. Perry, MD, director, oncology care model division leader, hematology/oncology, Crystal Run Healthcare, cited as a barrier “the amount of hoops that our practice and every other practice has to jump through that is not reimbursed, in order to get patients free drugs because $18,000 a month is impossible.

“Pharmacy benefit managers need to have better controls. Drug companies need to have better controls. We don’t want to thwart innovation, but we need to have access,” Perry said. “If the government can’t negotiate with a drug company, there needs to be some other cost-containment strategy. You can’t have no cost containment, and no [value-based] pathways, and no consequences. Something needs to happen. You have to chose one. You have to choose another. Maybe it’s a blend. I don’t know what the answer is. But what we have right now is unsustainable.”

“I think we all agree that the escalating costs are unsustainable,” added the panel’s moderator, Shalom Kalnicki, MD, chairman, department of radiation oncology, Albert Einstein College of Medicine and Montefiore Medical Center.

Below is GEN’s Top 10 A-List of top-selling prescription drugs with cancer indications. The drug that topped this list ranked third on GEN’s A-List of Top 15 Best-Selling Drugs of 2018, which included more than half of the cancer drugs that generated sufficient sales to be ranked here.

Top-selling drugs are ranked based on sales or revenue reported for 2018 by bio/pharma companies in press announcements, annual reports, investor materials, and/or conference calls. Each drug is listed by name, sponsor(s), type of drug, 2018 sales, 2017 sales, and the percentage change between both years.

The top 10-selling cancer drugs generated a combined $63.58 billion in sales in 2018, up 17.5% from $54.126 billion in 2017. Seven of this year’s top 10 showed year-over-year increases in sales, of which six enjoyed double-digit gains.

Ranking #15 through #11 among cancer best-sellers are Takeda/Johnson & Johnson’s Velcade® (bortezomib); Incyte/Novartis’ Jakafi®/Jakavi® (ruxolitinib); Genentech (Roche)’s Perjeta (pertuzumab); Merck & Co.’s Gardasil/Gardasil 9; and J&J’s Zytiga® (abiraterone acetate). The treatments generated between $2.274 billion and $3.498 billion last year.

10. Xtandi® (enzalutamide)

Astellas Pharma and Pfizer

Type of Drug: Androgen receptor inhibitor,

9. Ibrance® (palbociclib)

Pfizer

Type of Drug: Kinase inhibitor.

8. Neulasta/Peglasta (pegfilgrastim)

Amgen and Kyowa Hakko Kirin

Type of Drug: Leukocyte growth factor.

7. Imbruvica® (ibrutinib) 

Pharmacyclics (AbbVie) and Johnson & Johnson (J&J)

Type of Drug: Kinase inhibitor.

6. Rituxan®/MabThera (rituximab)

Genentech (Roche) and Biogen 2

Type of Drug: CD20-directed cytolytic antibody.

5. Avastin

Roche

Type of Drug: Vascular endothelial growth factor–directed antibody.

4. Herceptin

Roche (Genentech)

Type of Drug: HER2/neu receptor antagonist.

3. Keytruda

Merck & Co.

Type of Drug: Programmed death receptor-1 (PD-1)-blocking antibody.

2. Opdivo

Bristol-Myers Squibb (BMS) and Ono Pharmaceutical

Type of Drug: Programmed death receptor-1 (PD-1) blocking antibody.

1. Revlimid

Celgene

Type of Drug: Thalidomide analogue

References
1. Despite the year-over-year sales increase, Pfizer said international Ibrance revenues were negatively impacted by a one-time price adjustment to full-year 2017 revenues related to finalizing reimbursement agreements in certain developed Europe markets
2. Biogen receives a share of U.S. pre-tax profits on sales of Rituxan, which is marketed by Genentech (Roche). Sales figures do not include U.S. pre-tax profits generated by Biogen, since the company only discloses those profits combined with profits from Gazyva® (obinutuzumab), and does not break out each product separately. Biogen reported combined Rituxan-Gazyva pre-tax profits of $1.432 billion for 2018, and $1.316 billion for 2017.

THIS IS COPIEDFROM ANOTHER BLOG 

DUE TO IMPORTANT SO WE ARE SHARING THIS . TO ALL 

 For More Details click here on our youtube channel